Small molecule drug discovery

Syntekabio uses DMC to discover new drug candidates for various targets of domestic and global pharmaceutical companies, biotech and research institutes. We use an R-group DB for drug optimization and can secure new drug candidates in 2 years.

Neoantigen discovery

We are collaborating with cancer vaccine development companies, hospitals and research institutes on personalized neoantigens and shared neoantigens. After validation of the predicted antigen and production of a cancer vaccine, clinical research will be conducted for each patient.

Discovery & development

We conduct joint research with domestic and foreign pharmaceutical companies and research institutes on rare diseases, challenging genes, PROTACs, molecular adhesives and PPIs. We have established a system to achieve excellent research results through joint research and to shorten the time to market for new technologies.

Biochemical assay

To verify the efficacy of DMC-derived compounds, the binding strength is confirmed with global CROs such as eurofin and BPSbio. In addition, we are building a network with Wuxi, Sundia, etc. to synthesize compounds in a short time after generating derivatives using DMC, and we aim to provide quality services to our customers.

In vitro

Syntekabio has an in vitro assay network for cancer, infection, autoimmunity, allergies and diseases of the central nervous system. Cell based efficacy are performed at the best research institute and reliable and reproducible experimental results can be confirmed.

In vivo

We have a network of CROs for in vivo assay in cancer, immunotherapy, allergy, infectious diseases and CNS. The CROs are excellent domestic and international research institutes, have animal models for various diseases and can provide high quality data for drug efficacy testing and IND filing.